This is despite the fact that 95% of people with Hepatitis C can be completely cured within two or three months. It also said that by the first quarter of 2016, Gilead had accumulated over US$35bil in global revenue from Hepatitis C medicines since its launch in December 2013. “When cost is prohibitive, only a limited number of people will be treated and Hepatitis C infection will still be transmitted. “Malaysia using CL in making drugs affordable and tackling Hepatitis C through public health approach is a game changer. The move had also led to Gilead Sciences announcing on Aug 24 to include Malaysia in the Hepatitis C generic licensing agreement with several Indian manufacturers.

Source: The Star April 07, 2018 09:22 UTC